Maxmind Pharmaceutical GmbH — China registrations and re-registration filing lines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2026-11-09.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20220046 | Tadalafil Tablets 他达拉非片 | 2027-05-09 | 2026-11-09 |
| 国药准字HJ20240131 | Sildenafil Citrate Tablets 枸橼酸西地那非片 | 2029-11-14 | 2029-05-14 |
| 国药准字HJ20240132 | Sildenafil Citrate Tablets 枸橼酸西地那非片 | 2029-11-14 | 2029-05-14 |
| 国药准字HJ20240133 | Sildenafil Citrate Tablets 枸橼酸西地那非片 | 2029-11-14 | 2029-05-14 |
| 国药准字HJ20240161 | Levonorgestrel Tablets 左炔诺孕酮片 | 2029-12-05 | 2029-06-05 |
| 国药准字HJ20260032 | Alendronate Sodium Tablets 阿仑膦酸钠片 | 2031-04-13 | 2030-10-13 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.